T-Cell Cancer after CAR T-Cell Therapy
- 13 June 2024
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (22) , 2120-2121
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Unanswered questions following reports of secondary malignancies after CAR-T cell therapyNature Medicine, 2024
- CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaBlood, 2023
- Multiparameter prediction of myeloid neoplasia riskNature Genetics, 2023
- Long-term outcomes following CAR T cell therapy: what we know so farNature Reviews Clinical Oncology, 2023
- Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyBlood Advances, 2021
- Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasmsBlood Advances, 2020
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptorsNature Reviews Clinical Oncology, 2013
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003